Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press19710.17650/1726-9776-2013-9-1-68-73REVIEWОБЗОРTHE POSSIBILITIES AND MECHANISMS OF ACTION OF HORMONE THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCERВОЗМОЖНОСТИ И МЕХАНИЗМЫ ДЕЙСТВИЯ ГОРМОНАЛЬНОЙ ТЕРАПИИ У БОЛЬНЫХ КАСТРАЦИОННО-РЕЗИСТЕНТНЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫAlekseevB. Ya.АлексеевБ. Я.
Russian Federation
mailandrianov@gmail.comAndrianovA. N.АндриановА. Н.
Russian Federation
mailandrianov@gmail.comP.A. Herzen Moscow Oncology Research InstituteМНИОИ им. П.А. Герцена300320139168730108201401082014https://oncourology.abvpress.ru/oncur/article/view/197

Hormone therapy is a basic treatment for locally advanced and/or metastatic prostate cancer (PC); however, most patients become resistant to first-line therapy in the course of time. Abiraterone is a highly active, selective, irreversible CYP17 inhibitor that prevents the conversion of pregnenolone to dehydroepiandrostenedione and that of progesterone to androstenedione in the testes and adrenals, as well as directly in tumor tissue. This drug is able to considerably improve tumor-specific and overall survival rates in patients with castration-resistant PC (CRPC) and it has been approved by the U.S. Food and Drug Administration to treat this cohort of patients. Despite the efficacy of abiraterone, which has been proven during clinical trials, the disease progresses over time. This literature review deals with the possible mechanisms of resistance to abiraterone. A deep insight into the above mechanisms can open up fresh opportunities for resistance control and improve survival rates in patients with CRPC.

abiraterone acetateabirateronecastration-resistant prostate cancerhormone therapyабиратерона ацетатабиратеронкастрационно-резистентный рак предстательной железыгормональная терапия1. Lam J.S., Leppert J.T., Vemulapalli S.N. et al. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175: 27–34.Lam J.S., Leppert J.T., Vemulapalli S.N. et al. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175: 27–34.2. Holzbeierlein J., Lal P., LaTulippe E. et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgenresponsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217–27.Holzbeierlein J., Lal P., LaTulippe E. et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgenresponsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217–27.3. Montgomery R.B., Mostaghel E.A., Vessella R. et al. Maintance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447–54.Montgomery R.B., Mostaghel E.A., Vessella R. et al. Maintance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447–54.4. Titus M.A., Schell M.J., Lih F.B. et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653–7.Titus M.A., Schell M.J., Lih F.B. et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653–7.5. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253–61.Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253–61.6. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.7. de Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010;376:1147–54.de Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010;376:1147–54.8. Lheureux S., Joly F. Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer. Bull Cancer 2012;99:875–80.Lheureux S., Joly F. Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer. Bull Cancer 2012;99:875–80.9. Mostaghel E.A., Page S.T., Lin D.W. et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67:5033–41.Mostaghel E.A., Page S.T., Lin D.W. et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67:5033–41.10. Scher H.I., Beer T.M., Higano C.S. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 2010;375:1437–46.Scher H.I., Beer T.M., Higano C.S. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 2010;375:1437–46.11. Scher H.I., Buchanan G., Gerald W. et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004; 11:459–76.12. Stigliano A., Gandini O., Cerquetti L. et al. Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. J Endocrinol 2007;194:55–61.Scher H.I., Buchanan G., Gerald W. et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004; 11:459–76.12. Stigliano A., Gandini O., Cerquetti L. et al. Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. J Endocrinol 2007;194:55–61.13. Stanbrough M., Bubley G.J., Ross K. et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815–25.Stanbrough M., Bubley G.J., Ross K. et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815–25.14. Gelmann E.P. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001–15.Gelmann E.P. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001–15.15. Chen C.D., Welsbie D.S., Tran C. et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33–9.Chen C.D., Welsbie D.S., Tran C. et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33–9.16. Tomlins S.A., Mehra R., Rhodes D.R. et al. Integrative molecular concept modeling of prostate cancer prosression. Nat Genet 2007;39:41–51.Tomlins S.A., Mehra R., Rhodes D.R. et al. Integrative molecular concept modeling of prostate cancer prosression. Nat Genet 2007;39:41–51.17. Koivisto P., Kononen J., Palmberg C. et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314–9.Koivisto P., Kononen J., Palmberg C. et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314–9.18. Taplin M.E., Bubley G.J., Shuster T.D. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393–8.Taplin M.E., Bubley G.J., Shuster T.D. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393–8.19. Sun S., Sprenger C.C., Vessella R.L. et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715–30.Sun S., Sprenger C.C., Vessella R.L. et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715–30.20. Nupponen N., Visakorpi T. Molecular biology of progression of prostate cancer. Eur Urol 1999;35:351–4.Nupponen N., Visakorpi T. Molecular biology of progression of prostate cancer. Eur Urol 1999;35:351–4.21. Tamura K., Furihata M., Tsunoda T. et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007;67:5117–25.Tamura K., Furihata M., Tsunoda T. et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007;67:5117–25.22. Gregory C.W., Johnson R.T. Jr, Mohler J.L. et al. Androgen receptor stabilization in recurrent prostate cancer is assosiated with hypersensitivity to low androgen. Cancer Res 2001;61:2892–8.Gregory C.W., Johnson R.T. Jr, Mohler J.L. et al. Androgen receptor stabilization in recurrent prostate cancer is assosiated with hypersensitivity to low androgen. Cancer Res 2001;61:2892–8.23. Brooke G.N., Bevan C.L. The role of androgen receptor mutations in prostate cancer prosression. Curr Genomics 2009;10:18–25.Brooke G.N., Bevan C.L. The role of androgen receptor mutations in prostate cancer prosression. Curr Genomics 2009;10:18–25.24. Hu R., Dunn T.A., Wei S. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16–22.Hu R., Dunn T.A., Wei S. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16–22.25. Watson P.A., Chen Y.F., Balbas M.D. et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full=length androgen receptor. Proc Natl Acad Sci USA 2010;107:16759–65.Watson P.A., Chen Y.F., Balbas M.D. et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full=length androgen receptor. Proc Natl Acad Sci USA 2010;107:16759–65.26. Scott H.M., Mason J.I., Sharpe R.M. Steroidogenesis in the fetal testis and its susceptibility to disruption by exogenous compounds. Endocr Rev 2009;30:883–925.Scott H.M., Mason J.I., Sharpe R.M. Steroidogenesis in the fetal testis and its susceptibility to disruption by exogenous compounds. Endocr Rev 2009;30:883–925.27. Payne A.H., Hales D.B. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormone. Endocr Rev 2004;25:947–70.Payne A.H., Hales D.B. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormone. Endocr Rev 2004;25:947–70.28. Luu-The V., Bélanger A., Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22:207–21.Luu-The V., Bélanger A., Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22:207–21.29. Hoivik E.A., Lewis A.E., Aumo L., Bakke M. Molecular aspects of steroidogenic factor 1 (SF-1). Mol Cell Endocrinol 2010;315:27–39.Hoivik E.A., Lewis A.E., Aumo L., Bakke M. Molecular aspects of steroidogenic factor 1 (SF-1). Mol Cell Endocrinol 2010;315:27–39.30. Lin L., Achermann J.C. Steroidogenic factor-1 (SF-1, Ad4BP, NR5A1) and disorders of testis development. Sex Dev 2008;2:200–9.Lin L., Achermann J.C. Steroidogenic factor-1 (SF-1, Ad4BP, NR5A1) and disorders of testis development. Sex Dev 2008;2:200–9.31. Aesøy R., Mellgren G., Morohashi K., Lund J. Activation of cAMP-dependent protein kinase increases the protein level of steroidogenic factor-1. Endocrinology 2002;143:295–303.Aesøy R., Mellgren G., Morohashi K., Lund J. Activation of cAMP-dependent protein kinase increases the protein level of steroidogenic factor-1. Endocrinology 2002;143:295–303.32. Schimmer B.P., White P.C. Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. Mol Endocrinol 2010;24:1322–37.Schimmer B.P., White P.C. Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. Mol Endocrinol 2010;24:1322–37.33. Penning T.M., Byrns M.C. Steroid hormone transforming aldo-keto reductases and cancer. Ann NY Acad Sci 2009; 1155:33–42.Penning T.M., Byrns M.C. Steroid hormone transforming aldo-keto reductases and cancer. Ann NY Acad Sci 2009; 1155:33–42.34. Auchus R.J. The genetics, pathophysyology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 2001;30:101–19.Auchus R.J. The genetics, pathophysyology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 2001;30:101–19.35. Dreicer R., Agus D.B., MacVicar G.R. et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castratation-resistant metastatic prostate cancer: a phase I/II open label study. Genitourin Cancer Symp Proc 2010;89: abstr 103.Dreicer R., Agus D.B., MacVicar G.R. et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castratation-resistant metastatic prostate cancer: a phase I/II open label study. Genitourin Cancer Symp Proc 2010;89: abstr 103.36. Barrie S.E., Potter G.A., Goddard P.M. et al. Pharmacology of novel steroidal inhibitors of cytochrome P450 (17)alpha (17 aplha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50:267–73.Barrie S.E., Potter G.A., Goddard P.M. et al. Pharmacology of novel steroidal inhibitors of cytochrome P450 (17)alpha (17 aplha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50:267–73.37. Montgomery B., Mostaghel E., Nelson P. et al. Abiraterone suppresses castration resistant human prostate cancer growth in the absence of testicular and adrenal androgens. Presented at American Association for Cancer Research Special Conference: Advances in Prostate Cancer Research, San Diego, California, January 21–24, 2009.Montgomery B., Mostaghel E., Nelson P. et al. Abiraterone suppresses castration resistant human prostate cancer growth in the absence of testicular and adrenal androgens. Presented at American Association for Cancer Research Special Conference: Advances in Prostate Cancer Research, San Diego, California, January 21–24, 2009.38. O’Donnell A., Judson I., Dowsett M. et al. Hormonal impact of the 17-aplha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317-25.O’Donnell A., Judson I., Dowsett M. et al. Hormonal impact of the 17-aplha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317-25.39. Attars G., Reid A.H.M., Yap T.A. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;28:4563–71.Attars G., Reid A.H.M., Yap T.A. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;28:4563–71.40. Ryan C.J., Smith M.R., Fong L. et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who recieved prior ketoconazole. J Clin Oncol 2010;28:1481–8.Ryan C.J., Smith M.R., Fong L. et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who recieved prior ketoconazole. J Clin Oncol 2010;28:1481–8.41. Attard G., Reid A.H., Auchus R.J. et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012;97:507–16.Attard G., Reid A.H., Auchus R.J. et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012;97:507–16.42. de Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.de Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.43. Ryan C.J., Smith M.R., de Bono J.S. et al. Interim analysis (IA) results of COU-AA-302, a randomized, phaze III study of abiraterone acetate (AA) in chemotherapy-naive patients (PTS) with metastatic castration-resistant prostate cancer (mCPRC). J Clin Oncol 2012;30: abstr. LBA4518.Ryan C.J., Smith M.R., de Bono J.S. et al. Interim analysis (IA) results of COU-AA-302, a randomized, phaze III study of abiraterone acetate (AA) in chemotherapy-naive patients (PTS) with metastatic castration-resistant prostate cancer (mCPRC). J Clin Oncol 2012;30: abstr. LBA4518.44. Mostaghel E.A., Marck B.T., Plymate S.R. et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17(18):5913–25.Mostaghel E.A., Marck B.T., Plymate S.R. et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17(18):5913–25.45. Hornberg E., Ylitalo E.B., Crnalic S. et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 6(4): e19059.Hornberg E., Ylitalo E.B., Crnalic S. et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 6(4): e19059.